Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00718965 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 826
- Enrollment target
NCT00718965: Clinical Trial Phase 3 study, sponsored by Sanofi.
NCT00718965 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 826 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00718965, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 826 participants
- Enrollment target
Study Summary
The present study is aiming at assessing the efficacy and safety of AVE5530 (25mg and 50mg) in a double-blind comparison with placebo in the management of patients with primary hypercholesterolemia. The main objective is to evaluate the effects of AVE5530 on LDL-C level reduction as adjunct to a controlled diet. The effects of AVE5530 on other lipid parameters will be assessed as secondary objectives.
Interventions
- DRUG Placebo
- DRUG AVE5530
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 826 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Why NCT00718965 stopped before completion
NCT00718965 is an interventional study that assigns participants to a tested intervention. The registered 826 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00718965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00718965 about?
NCT00718965 is a clinical study titled "Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia". The present study is aiming at assessing the efficacy and safety of AVE5530 (25mg and 50mg) in a double-blind comparison with placebo in the management of patients with primary hypercholesterolemia. The main objective is to evaluate the effects of AVE5530 on LDL-C level reduction as adjunct to a con...
What is the current status of trial NCT00718965?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 826 participants. The study started on 2008-07. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00718965?
The interventions under investigation include: Placebo (DRUG), AVE5530 (DRUG).
Who is sponsoring clinical trial NCT00718965?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00718965's enrollment target sits among peer trials
826 400th of 2000 higher than 1,601 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03547973 · 827 participants · Phase 2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
- NCT05630482 · 825 participants · NA
Randomized Trial of Healthy Family Foundations
- NCT06097728 · 825 participants · Phase 3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
- NCT07102641 · 825 participants · Phase 4
Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia